MetaCap

Sarepta Therapeutics Inc. (SRPT)

NASDAQ: SRPTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.33-0.84 (-5.93%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SRPT stock chart

Technical analysis

Key statistics

All statistics
P/E (TTM)
666.50
52-week range
13.25 – 24.68
Day range
13.25 – 14.47
Volume / Avg
2.24M / 2.70M
Beta
—

52-week range

$13.25$24.68

SRPT stock today

Shares of Sarepta Therapeutics (SRPT) finished lower on Nov 20 at $13.33, a drop of 5.93% or $0.84 per share, versus the S&P 500's 3.70% decline. Shares are 46.0% below their 52-week high of $24.68, set on Jan 26, 2026 and 0.6% above the 52-week low of $13.25, near the bottom of the past year's range. SRPT is down 38.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 24.6%.

At 666.5x trailing earnings, Sarepta Therapeutics trades above the peer-group median of 7.2x. Its forward P/E of 8.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Sarepta Therapeutics

Company profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Michael E. Severino M.D.
Headquarters
Cambridge, MA
Employees
835

Financial highlights

Full financials

In fiscal 2025, Sarepta Therapeutics generated $2.20 billion in revenue, up 15.6% from fiscal 2024, its 10th consecutive year of revenue growth. Sarepta Therapeutics reported a net loss of $713.4 million, compared with net income of $235.2 million a year earlier. Gross margin was 98.8% and operating margin -31.8%.

Sarepta Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.20B$1.90B$1.24B$933.01M$701.89M
Growth+15.58%+52.97%+33.26%+32.93%+29.96%
Net income$-713.41M$235.24M$-535.98M$-703.49M$-418.78M
EPS (diluted)$-7.13$2.34$-5.80$-8.03$-5.15

Analyst forecast

Forecast

Consensus (24 analysts)

hold

Avg. price target

$21.77+63.32%

  • Strong buy 0
  • Buy 7
  • Hold 13
  • Sell 2
  • Strong sell 2

Target range

Low $5.00High $38.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.28 vs $0.17
Surprise
-264.71%

SRPT news

All SRPT news

Sarepta Therapeutics peers

Health Care sector
SRPT peer companies
CompanyPrice% ChgMarket capCompare
KLRAKailera Therapeutics Inc.11.02-4.84%$1.43Bvs SRPT
ADRXADARx Pharmaceuticals Inc.12.79-9.68%$1.42Bvs SRPT
DMRADamora Therapeutics Inc.23.22-4.44%$1.44Bvs SRPT
NRIXNurix Therapeutics Inc.12.85-5.55%$1.40Bvs SRPT
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs SRPT
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs SRPT
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs SRPT
QUREuniQure N.V.19.35-4.35%$1.36Bvs SRPT

Indexes, lists and sector

Sarepta Therapeutics stock FAQ

What is Sarepta Therapeutics's stock price today?

SRPT last traded at $13.33 as of Nov 20, 4:00 PM EST, down 5.93% on the day. Prices are delayed at least 15 minutes.

Does Sarepta Therapeutics pay a dividend?

No. Sarepta Therapeutics does not currently pay a regular cash dividend.

What is SRPT's P/E ratio?

SRPT trades at a trailing P/E ratio of 666.50 and a forward P/E of 8.87, compared with a median of 7.2 for its closest peers.

Who is Sarepta Therapeutics's CEO?

Dr. Michael E. Severino M.D. is the chief executive officer of Sarepta Therapeutics Inc., which has about 835 employees.

Has SRPT ever split its stock?

Yes. The most recent SRPT stock split was a 1-for-6 split on Jul 12, 2012.

What is the SRPT 52-week high?

The 52-week high for SRPT is $24.68 and the 52-week low is $13.25. The stock is currently 46.0% below its high.

Compare SRPT